Autoimmunity Reviews

Papers
(The H4-Index of Autoimmunity Reviews is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board278
Editorial Board180
“Fibromyalgia syndrome” related to Essure devices153
Leflunomide: A safe and effective alternative in systemic lupus erythematosus148
Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review112
Editorial Board105
Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis100
T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch94
The rationale for the use of corticosteroids in early severe Guillain-Barré syndrome89
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence84
Issues in autoantibody tests used in the classification criteria for autoimmune rheumatic diseases: the laboratory autoimmunologist's perspective77
Epidemiological patterns and in-hospital mortality in ANCA-associated vasculitis: Insights from Spain's National Health Data (2016–2022)76
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis76
Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases75
Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management72
Susac syndrome: A scoping review72
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders72
The role of musculoskeletal ultrasound in difficult-to-treat RA: Insights from a systematic literature review69
Endometriosis and autoimmunity68
Editorial Board66
A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. “Epidemiology 66
Can anticoagulation be withdrawn in APS patients after aPL negativization?65
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy63
Seronegative autoimmune diseases: A challenging diagnosis62
Conceiving complexity: Biological mechanisms underpinning the lasting effect of pregnancy on multiple sclerosis outcomes57
Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered57
Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review56
Autoimmunity in vitiligo: Therapeutic implications and opportunities54
Fecal microbiota transplantation in autoimmune diseases – An extensive paper on a pathogenetic therapy54
Human abdominal aortic aneurysm (AAA): Evidence for an autoimmune antigen-driven disease.51
WITHDRAWN: Global incidence trends of autoimmune diseases from 1990 to 2021 and projections to 2050: A systemic analysis of the global burden of disease study 202151
Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease49
The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned48
Autoimmune pre-disease48
To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate48
Rebalancing redox homeostasis: A pivotal regulator of the cGAS-STING pathway in autoimmune diseases46
Understanding the effects of Janus kinase inhibitors on the cardiovascular system in comparison to main biological DMARDs in rheumatoid arthritis46
Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination45
Homocysteine as a trigger and potential therapeutic target for autoimmune diseases45
The immune system in Hashimoto's thyroiditis: Updating the current state of knowledge on potential therapies and animal model construction42
Psychiatric manifestations of autoimmune encephalitis42
Cardiovascular outcome in adult-onset Kawasaki disease42
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature42
0.04454517364502